advertisement
OBJECTIVE: To compare the efficacy of brimonidine 0.2% with apraclonidine 0.5% in preventing intraocular pressure (IOP) elevations after anterior segment laser surgery. DESIGN: A double-masked, randomized clinical trial. PARTICIPANTS: Sixty-six patients underwent either laser peripheral iridotomy, argon laser trabeculoplasty, or Nd:YAG laser capsulotomy. INTERVENTION: Eyes received either one drop of brimonidine 0.2% or apraclonidine 0.5% before laser surgery. MAIN OUTCOME MEASURES: IOP, heart rate, and blood pressure were measured before laser surgery and at one, three, and 24 hours and one week after laser surgery. RESULTS: Before the laser treatment, 33 patients (50.0%) received brimonidine 0.2%, and 33 patients (50.0%) received apraclonidine 0.5%. Eight of 33 patients (24.2%) in the brimonidine-treated group and nine of 33 patients (27.3%) in the apraclonidine group had postoperative IOP increased of 5 mmHg or more. This was not statistically different (p = 0.80). By the time of the last follow-up examination, three of 33 patients (9.1%) in the brimonidine-treated group and three of 33 (9.1%) in the apraclonidine group had IOP increases of 10 mmHg or more. This was also not statistically different (p
Dr T.C. Chen, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA. teresa_chen@meei.harvard.edu
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
12.2 Laser iridotomy (Part of: 12 Surgical treatment)
12.4 Laser trabeculoplasty and other laser treatment of the angle (Part of: 12 Surgical treatment)